Curriculum Vitae

The present curriculum serves as a self-certification according to D.P.R. 445/2000.

The processing of personal data is authorized pursuant to D.L. 196/03.

Prof. MARCO PISTIS

Personal Information

Full Name: Marco Pistis
Date and Place of Birth:
Citizenship: Italian
Work Address: Department of Biomedical Sciences
University Campus
09042 Monserrato (CA), Italy
Phone:
Mobile:
Email: mpistis@unica.it
Website: http://people.unica.it/marcopistis/

---

1) Education

December 16, 1992

- Doctor of Medicine and Surgery (110/110 cum laude) from the University of Cagliari.

December 19, 1997

- Specialization in Pharmacology, Clinical Pharmacology track (50/50 cum laude) at the School of Specialization in Pharmacology, University of Cagliari.

---

2) Research Activities and Professional Experience

January 2022 – Present

- Clinical activity at the Complex Structure of Clinical Pharmacology, University Hospital of Cagliari.

October 2014 – Present

- Full Professor of Pharmacology (SSD BIO/14) at the Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, Faculty of Medicine and Surgery, University of Cagliari.

November 2001 – October 2014

- Associate Professor of Pharmacology (SSD BIO/14) at the Faculty of Medicine and Surgery (until October 15, 2007, at the Faculty of Education), University of Cagliari. Affiliated with the Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology (until December 2011, Department of Neuroscience "B. B. Brodie").

January 2000 – October 2001

- University Researcher in Physiological Psychology and Psychobiology (M-PSI-02) at the Faculty of Education Sciences, Psychology Program, University of Cagliari. Affiliated with the Department of Neuroscience "B. B. Brodie," University of Cagliari.

March 1999 – January 2000

- Contract Researcher at the University Spin-Off "Consortium for Neuropsychopharmacological Research (Neurosciences s.c.ar.l.)"

October 1995 – September 1998

- Postdoctoral Research Assistant at the Department of Pharmacology and Neuroscience, Ninewells Hospital, University of Dundee (UK). Project funded by the Medical Research Council under the supervision of Prof. Jeremy J. Lambert.

June 1993 – July 1993

- Short-term fellowship funded by the Autonomous Region of Sardinia, Department of Neuroscience, University of Health Science, The Chicago Medical School, Chicago (USA).

February 1991 – September 1995

- Scientific research activities at the Department of Neuroscience "B.B. Brodie," University of Cagliari, as an internal student (February 1991 – December 1992), research assistant (December 1992 – October 1993), and Pharmacology Resident (November 1993 – September 1995).

Main Research Lines

2004–present

- Study of the endocannabinoid system in an animal model of neurodevelopmental alteration induced by maternal immune activation [6, 9].
- Identification of a novel molecular target with translational applications in the pharmacological treatment of nocturnal frontal lobe epilepsy (publications [5, 38, 53]), depression (publication [40]), schizophrenia (publications [14, 23, 31, 39]), enhancement of opioid analgesia [19], and nicotine addiction: interaction between nuclear PPAR-α receptors and nicotinic acetylcholine receptors (publications [13, 16, 25, 27, 28, 34, 36, 37, 42, 46, 48, 50, 52, 53, 59, 61, 63–65, 68]).

- Neuropharmacological characterization of novel cognitive enhancer drugs [2, 4, 12, 20, 26, 33].
- Neuropharmacological and neurophysiological characterization of neurons in a recently identified structure, the rostromedial tegmental nucleus (RMTg), a major inhibitory input to dopaminergic nuclei (publications [30, 44, 47, 51, 54, 55, 60]), involved in the mechanism of action of drugs of abuse.
- In vitro and in vivo analysis of the physiological and pathophysiological role of the endocannabinoid system in the modulation of activity and synaptic plasticity in dopaminergic neurons (publications [22, 32, 35, 45, 56–58, 66, 68, 71–73, 77, 78]).
- Electrophysiological study of the acute and chronic effects of cannabinoids on neuronal activity in brain regions of the limbic system, particularly the ventral tegmental area and its projection areas: nucleus accumbens, basolateral amygdala, and prefrontal cortex (publications [3, 41, 43, 49, 62, 67, 69, 70, 74, 75, 79, 80, 83–85]).
- Other activities and collaborations [1, 7, 8, 10, 11, 15, 17, 18, 21, 24, 29].

1999–2000

- Electrophysiological characterization of the actions of γ-hydroxybutyrate (GHB), its structural analogs, and GABAB receptor agonists and antagonists on neurons of the reward systems (publication [76]).
- Study of the molecular mechanisms of voluntary alcohol consumption and alcohol aversion in animal models: identification of a mutation in the α6 subunit of the GABAA receptor in Sardinian non-preferring rats, heterologous expression of mutated native receptors in *Xenopus laevis* oocytes, and pharmacological characterization (publications [81, 86]).
- Biochemical and electrophysiological study of γ-hydroxybutyrate (GHB) and its structural analogs (publication [82]).

1995–1998

- In vitro electrophysiological study of allosteric modulators of recombinant GABAA and glycine receptors heterologously expressed in *Xenopus laevis* oocytes (publications [88, 89, 94]).
- Combined single-site mutagenesis and electrophysiological studies to identify the amino acid residues constituting the binding site for general anesthetics on GABAA and glycine receptors (publications [92, 93]).
- Pharmacological and functional identification and characterization of a novel subunit of the 5-HT3 receptor (publication [90]).

1991–1995

- Electrophysiological characterization of dopaminergic and serotonergic systems during alcohol or morphine withdrawal syndrome: identification of a profound and persistent depression of the dopaminergic system as a common feature of withdrawal syndromes, and a possible neurophysiological correlate of dysphoria and craving (publications [87, 91, 95–103]).

---

3) Other Activities and Appointments

October 2024 – present
Member of the Board of Directors of the Italian Society of Pharmacology (SIF)

June 2023 – present
Member of the Regional Ethics Committee (Territorial Ethics Committee) of the Region of Sardinia

November 2022 – present
Member of the Executive Committee of the Clinical Pharmacology Section of the Italian Society of Pharmacology (SIF)

October 2017 – November 2022
Member of the Board of Directors of the Italian Society of Pharmacology (SIF)

October 2015 – present
Member of the Regional Commission for the Hospital Pharmaceutical Formulary

April 2015 – present
Director of the Postgraduate School of Clinical Pharmacology and Toxicology, University of Cagliari

June 2015 – present
Departmental Representative (Department of Biomedical Sciences) on the Committee for the IBRO-Kemali Prize

June 2015 – present
Member of the University Committee for Patents and Spin-Offs

June 2015 – June 2021
Deputy Director of the Department of Biomedical Sciences

February 2014
National Scientific Qualification as Full Professor (Professore di I fascia) in the academic discipline 05/G1 (Pharmacology, Clinical Pharmacology, and Pharmacognosy)

November 2012 – present
Head of the Neuroscience and Clinical Pharmacology Section, Department of Biomedical Sciences, University of Cagliari

May 2012 – present
Registered Expert in the MIUR (Italian Ministry of University and Research) Database, pursuant to Article 7, Paragraph 1, of Legislative Decree no. 297 of 27 July 1999. Approved by Decree no. 30/Ric. of 2 February 2012

November 2010 – present
Research Associate at the Institute of Neuroscience, National Research Council (CNR)

April 2009 – present
Registered Expert in the Ministry of Economic Development's database for technological innovation (Directorate Decree of 1 April 2010, no. 79/RIC, published in Official Gazette no. 127 of 4 June 2009; registration confirmed in August 2016). This role involves the evaluation of

precompetitive research and innovation projects under Article 14 of Law no. 46 of 17 February 1982 (ex-ante, ongoing, and ex-post evaluations)

October 2007 – December 2011
Deputy Director of the "B.B. Brodie" Department of Neuroscience, University of Cagliari

October 2007 – December 2011
Head of the Neurophysiology and Neurochemistry Section, Department of Neuroscience

4) Teaching Activities

Teaching in University Degree Programs

1. **Current and Past Teaching Appointments:**
   a. *Pharmacology* (Scientific Disciplinary Sector: BIO-14), Faculty of Medicine and Surgery, Degree Course in Medicine and Surgery (from academic year 2007/2008 to 2012/2013, co-teaching in 2013/2014).
   b. *Pharmacology* (BIO-14), Faculty of Medicine and Surgery, Degree Course in Dentistry and Dental Prosthetics, University of Cagliari.
   c. *Pharmacology* (BIO-14), Faculty of Medicine and Surgery, Degree Course in Dental Hygiene, University of Cagliari.
   d. *Pharmacology* (BIO-14), Faculty of Medicine and Surgery, Degree Course in Nursing, University of Cagliari.
   e. *Pharmacology* (BIO-14), Faculty of Medicine and Surgery, Degree Course in Midwifery, University of Cagliari (from academic year 2007/2008 – present).
   f. *Pharmacology (Psychopharmacology)* (BIO-14), Faculty of Education, Degree Course in Psychology, University of Cagliari (from academic year 2000/2001 to 2008/2009).
2. **Additional Teaching Appointments:**
   a. *Physiology* (BIO-09), Faculty of Education, Degree Course in Psychology, University of Cagliari (from academic year 2000/2001 to 2008/2009).
   b. *Physiological Psychology* (M-PSI-02), Faculty of Education, Degree Course in Psychology, University of Cagliari (from academic year 2000/2001 to 2008/2009).
   c. *Neuropsychology* (M-PSI-02), Faculty of Education, Degree Course in Primary Education, University of Cagliari (from academic year 2000/2001 to 2003/2004).
   d. *Anatomical and Physiological Foundations of Mental Activity* (M-PSI-02), Faculty of Education, Degree Course in Psychology, University of Cagliari (from academic year 2000/2001 to 2002/2003).

PhD Program

- **2013–2019:** Deputy Coordinator of the PhD Program in Neuroscience
- **2004–present:** Member of the Faculty Board of the PhD Program in Neuroscience, University of Cagliari
- Supervisor of 6 PhD students in Neuroscience

Postgraduate Specialization Schools

- Lecturer in *Pharmacology* for the Specialization Schools in Clinical Pharmacology, Medical Genetics, Food Sciences, Neurophysiology, and Neurology.

5) Participation in Research Projects and Funding Obtained

Grants Awarded as Principal Investigator or Local Unit Coordinator

1. **PRIN2022 PNRR** (Italian Ministry of University and Research): *Investigation of gut-brain axis in autism spectrum disorders: potential pathogenic role and pharmacological control of gut microbiota-derived extracellular vesicles in MIA offspring* – Prot. P20229CCLB (Local Unit Coordinator)
2. **PRIN2022** (MIUR): *Understanding the link between the immune system and neurodevelopment in the maternal immune activation model of schizophrenia: novel insight and experimental therapeutic approach* – Prot. 2022NSLB3Z (National Coordinator and Local Unit Coordinator)
3. **POS Call 2022 – Health Operational Plan** (Ministry of Health): Project HUB2B, coordinated by IRCCS Gaslini (Head of the Pharmacology Unit)
4. **Decentralized Cooperation Call 2022** (Autonomous Region of Sardinia): *Ukraine: Support to the healthcare system for non-communicable diseases and equitable drug distribution in the context of war* (Scientific Coordinator)
5. **RAS – Basic Research Projects (L.R. 7/2007)**: *Innovative pharmacological therapies and nutraceutical approaches for neuroinflammation in psychiatric and neurodegenerative diseases*, 2018 (Coordinator)
6. **Proof of Concept 2018** (MIUR): *Characterization of specific properties of conjugated linoleic acid (CLA) in phospholipid form for the treatment of psychiatric disorders with neuroinflammatory basis, and identification of biomarkers of its therapeutic efficacy* (Co-PI, PI: Prof. Sebastiano Banni)
7. **PRIN2017** (MIUR): *Bioenergetics and inflammation: novel insights for new therapeutic approaches in Alzheimer's Disease* – Prot. 2017YH3SXK (National Coordinator and Local Unit Coordinator)
8. **Banco di Sardegna Foundation (2012 Call)**: *A new therapeutic target for nocturnal frontal lobe epilepsy: preclinical studies*
9. **FIRE-AICE Call 2011**: *Interactions between PPARα nuclear receptors and nicotinic acetylcholine receptors as a novel strategy in pharmacoresistant epilepsies: preclinical and translational studies*
10. **PRIN2009** (MIUR): *Bio-molecular, immune, and spinal/supraspinal morpho-functional changes in a murine model of neuropathic pain: therapeutic perspectives using human mesenchymal cells and pharmacological manipulation of purinergic signaling* – Prot. 200928EEX4_002 (Local Unit Coordinator)
11. **PRIN2005** (MIUR): *Exposure to cannabinoids and alcohol during adolescence: behavioral and electrophysiological study in an animal model of voluntary alcohol consumption* (National Coordinator and Local Unit Coordinator)
12. **Project funded by the Autonomous Region of Sardinia – Health Department** (2003–2004): *Cannabis use during preadolescence: potential long-term consequences on the nervous system*
13. **Local research projects** (ex 60% quota) funded from 2001 to 2013
14. **"Young Researchers" Project** (University of Cagliari), funded in 2002

15. **"Young Researchers" Project** funded by CNR – Agenzia 2000

Participation in the Following Funded National and International Research Projects

1. **RAS – Basic Research Projects (L.R. 7/2007)**, 2008: *Role of nuclear PPAR-α receptors and their endogenous ligands in the neurobiological mechanisms of nicotine addiction and cognitive dysfunctions in schizophrenia* (PI: Prof. W. Fratta)
2. **Philip Morris External Research Program 2007**: *Neurobiological basis of nicotine addiction: involvement of the endocannabinoid system* (PI: Prof. W. Fratta)
3. **PRIN 2003**: *Cannabinoid use during prenatal and prepubertal periods: neurophysiological and neurochemical study in the limbic system* (National Coordinator and Local Unit Coordinator from 2004, replacing Prof. Gian Luigi Gessa)
4. **PRIN 2001**: *Abuse and rewarding properties of gamma-hydroxybutyric acid (GHB)* (Unit Coordinator; National PI: Prof. G.L. Gessa)
5. **FIRB 2001**: *Addiction models: molecular and functional correlates* (Unit Coordinator from 2004, replacing Prof. G.L. Gessa)
6. **COFINLAB 2000**: *Center of Excellence for the Neurobiology of Addiction* (Responsible for the Research Line from 2004, replacing Prof. G.L. Gessa)

---

6) Membership in Scientific Societies

Member of the **Italian Society of Pharmacology**, **Italian Society for Neuroscience**, **Society for Neuroscience**, and **International Cannabinoid Research Society**

---

7) Awards and Honors

- **1995**: Research Fellowship from the Italian Society of Pharmacology (SIF) for research abroad
- **2003**: *Farmindustria-SIF Award* for Preclinical Pharmacology Research
- **2006**: *ECNP Fellowship Award* and *Poster Award* (European College of Neuropsychopharmacology)

---

8) Invited Presentations at Conferences and Seminars

National Conferences and Seminars
(2005–2019): Speaker at numerous national congresses and symposia organized by SINS, SIF, ASL health authorities, and universities on topics ranging from neurodevelopment, psychiatric disorders, addiction, dual diagnosis, pharmacological therapies, to public health.

International Conferences and Seminars
(2003–2022): Invited speaker at major international events, including the International Cannabinoid Research Society (ICRS) meetings, Gordon Research Conferences, ECNP Congresses, Society for Neuroscience Annual Meeting, Mediterranean Neuroscience Society, and the World Congress of

Inflammation, among others. Presentations addressed cutting-edge research on cannabinoids, addiction, dopamine systems, neuroinflammation, and innovative pharmacological targets.

---

9) Peer Review Activity

- Member of the **Editorial Board** of *International Journal of Neuropsychopharmacology* and *Frontiers in Pharmacology*
- *Ad hoc reviewer* for:
  Trends in Pharmacological Sciences, Neuropsychopharmacology, Molecular Pain, British Journal of Pharmacology, Brain Research, Molecular Neurobiology, Neuropharmacology, Journal of Neuroscience Methods, NeuroReport, Neuroscience Letters, Neurobiology of Aging, Acta Psychiatrica Scandinavica, Behavioral Brain Research, Theoretical Biology and Medical Modelling, PNAS, Trends in Neurosciences, European Neuropsychopharmacology, PLOS One

---

10) Experience in Project Evaluation

- **2010**: External reviewer for the *Wellcome Trust* (UK)
- **2012**: External reviewer for the *Medical Research Council (MRC)* (UK)
- **2013**: External reviewer for *French Research Agency (SAMENTA)* and *Czech Research Agency*
- **2015–2018**: Reviewer for research funding programs of the Universities of Verona and Sassari, the Ministry of Economic Development (POR projects), and regional programs (ASTER Emilia Romagna, FILSE Liguria)

Patent Ownership

- **Co-inventor of the international patent**:
  Banni Sebastiano, Melis Miriam, Pistis Marco, Sogos Valeria (2015). Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with neuroinflammatory and neurodegenerative basis.
  WO2016016790 A1

8) Bibliometric Data

- **Average Impact Factor:** 5.616
- **H-index (Scopus):** 46
- **Total Citations (Scopus):** 6464

---

1. Pistis, M., *The Evolving Challenge of New Psychoactive Substances: Understanding the Risks and Behavioral Effects of Novel Analogs of Dissociative Anesthetics.* (2024) **J Pharmacol Exp Ther**. 390(1): p. 11-13.

2. Sagheddu, C., T. Stojanovic, S. Kouhnavardi, A. Savchenko, A.M. Hussein, M. Pistis, F.J. Monje, R. Plasenzotti, M. Aufy, C.R. Studenik, J. Lubec, and G. Lubec, *Cognitive performance in aged rats is associated with differences in distinctive neuronal populations in the ventral tegmental area and altered synaptic plasticity in the hippocampus.* (2024) **Front Aging Neurosci**. 16: p. 1357347.

3. Ferre, S., A. Kofalvi, F. Ciruela, Z. Justinova, and M. Pistis, *Targeting corticostriatal transmission for the treatment of cannabinoid use disorder.* (2023) **Trends Pharmacol Sci**.

4. Lubec, J., A.M. Hussein, P. Kalaba, D.D. Feyissa, E. Arias-Sandoval, A. Cybulska-Klosowicz, M. Bezu, T. Stojanovic, V. Korz, J. Malikovic, N.Y. Aher, M. Zehl, V. Dragacevic, J.J. Leban, C. Sagheddu, J. Wackerlig, M. Pistis, M. Correa, T. Langer, E. Urban, H. Hoger, and G. Lubec, *Low-Affinity/High-Selectivity Dopamine Transport Inhibition Sufficient to Rescue Cognitive Functions in the Aging Rat.* (2023) **Biomolecules**. 13(3).

5. Manca, C., R. Coa, E. Murru, G. Carta, G. Pinna, R. Sanfilippo, L. Polizzi, M. Pistis, P. Follesa, M. Puligheddu, and S. Banni, *Identification of metabolic biomarkers of chronic vagus nerve stimulation (VNS) in subjects with drug-resistant epilepsy (DRE).* (2023) **Epilepsia Open**.

6. Mostallino, R., M. Santoni, C. Sagheddu, V. Serra, V. Orru, M. Pistis, and M.P. Castelli, *The PPARalpha agonist fenofibrate reduces the cytokine imbalance in a maternal immune activation model of schizophrenia.* (2023) **Eur J Pharmacol**. 961: p. 176172.

7. Sagheddu, C., E. Cancedda, F. Bagheri, P. Kalaba, A.L. Muntoni, J. Lubec, G. Lubec, F. Sanna, and M. Pistis, *The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study.* (2023) **Int J Neuropsychopharmacol**. 26(11): p. 784-795.

8. Sagheddu, C., P. Devoto, S. Aroni, P. Saba, M. Pistis, and G.L. Gessa, *Combined alpha(2)- and D(2)-receptor blockade activates noradrenergic and dopaminergic neurons, but extracellular dopamine in the prefrontal cortex is determined by uptake and release from noradrenergic terminals.* (2023) **Front Pharmacol**. 14: p. 1238115.

9. Santoni, M., C. Sagheddu, V. Serra, R. Mostallino, M.P. Castelli, F. Pisano, M. Scherma, P. Fadda, A.L. Muntoni, E. Zamberletti, T. Rubino, M. Melis, and M. Pistis, *Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring.* (2023) **Brain Behav Immun**. 109: p. 271-284.

10. Armocida, B., B. Formenti, S. Ussai, E. Missoni, C. De Marchi, M. Panella, G. Onder, L. Mancini, M. Pistis, M. Martuzzi, and F. Barone-Adesi, *Decarbonization of the Italian healthcare system and European funds. A lost opportunity?,* (2022) **Front Public Health**. 10: p. 1037122.

11. Armocida, B., S. Ussai, M. Pavlovych, M. Valente, E. Missoni, M. Pistis, B. Lauria, F. Bustreo, and G. Onder, *Older people: forgotten victims amid the Ukrainian humanitarian disaster.* (2022) **Lancet Public Health**.

12. Kouhnavardi, S., A. Ecevitoglu, V. Dragacevic, F. Sanna, E. Arias-Sandoval, P. Kalaba, M. Kirchhofer, J. Lubec, M. Niello, M. Holy, M. Zehl, M. Pillwein, J. Wackerlig, R. Murau, A. Mohrmann, K.R. Beard, H.H. Sitte, E. Urban, C. Sagheddu, M. Pistis, R. Plasenzotti, J.D. Salamone, T. Langer, G. Lubec, and F.J. Monje, *A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.* (2022) **Biomolecules**. 12(7).

13. Murru, E., G. Carta, C. Manca, A. Saebo, M. Santoni, R. Mostallino, M. Pistis, and S. Banni, *Dietary Phospholipid-Bound Conjugated Linoleic Acid and Docosahexaenoic Acid Incorporation Into Fetal Liver and Brain Modulates Fatty Acid and N-Acylethanolamine Profiles.* (2022) **Front Nutr**. 9: p. 834066.

14. Murru, E., A.L. Muntoni, C. Manca, S. Aroni, M. Pistis, S. Banni, and G. Carta, *Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARalpha Agonist Fenofibrate-Treated Mice.* (2022) **Int J Mol Sci**. 24(1).

15. Palmas, M.F., M. Etzi, A. Pisanu, C. Camoglio, C. Sagheddu, M. Santoni, M.F. Manchinu, M. Pala, G. Fusco, A. De Simone, L. Picci, G. Mulas, S. Spiga, M. Scherma, P. Fadda, M. Pistis, N. Simola, E. Carboni, and A.R. Carta, *The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex.* (2022) **Cells**. 11(17).

16. Santoni, M., R. Frau, and M. Pistis, *Transgenerational Sex-dependent Disruption of Dopamine Function Induced by Maternal Immune Activation.* (2022) **Front Pharmacol**. 13: p. 821498.

17. Ussai, S., C. Chillotti, E. Stochino, A. Deidda, G. Ambu, L. Anania, A. Boccalini, F. Colombo, A. Ferrari, D. Pala, E. Puddu, G. Rapallo, and M. Pistis, *Building the Momentum for A Stronger Pharmaceutical System in Africa.* (2022) **Int J Environ Res Public Health**. 19(6).

18. Ussai, S., M. Pistis, E. Missoni, B. Formenti, B. Armocida, T. Pedrazzi, F. Castelli, L. Monasta, B. Lauria, and I. Mariani, *"Immuni" and the National Health System: Lessons Learnt from the COVID-19 Digital Contact Tracing in Italy.* (2022) **Int J Environ Res Public Health**. 19(12).

19. Congiu, M., L. Micheli, M. Santoni, C. Sagheddu, A.L. Muntoni, A. Makriyannis, M.S. Malamas, C. Ghelardini, L. Di Cesare Mannelli, and M. Pistis, *N-Acylethanolamine Acid Amidase Inhibition Potentiates Morphine Analgesia and Delays the Development of Tolerance.* (2021) **Neurotherapeutics**.

20. Lubec, J., P. Kalaba, A.M. Hussein, D.D. Feyissa, M.H. Kotob, R.R. Mahmmoud, O. Wieder, A. Garon, C. Sagheddu, M. Ilic, V. Dragacevic, A. Cybulska-Klosowicz, M. Zehl, J. Wackerlig, S.B. Sartori, K. Ebner, S. Kouhnavardi, A. Roller, N. Gajic, M. Pistis, N. Singewald, J.J. Leban, V. Korz, J. Malikovic, R. Plasenzotti, H.H. Sitte, F.J. Monje, T. Langer, E. Urban, C. Pifl, and G. Lubec, *Reinstatement of synaptic plasticity in the aging brain through specific dopamine transporter inhibition.* (2021) **Mol Psychiatry**.

21. Pala, D. and M. Pistis, *Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology.* (2021) **Front Pharmacol**. 12: p. 622554.

22. Pintori, N., M.P. Castelli, C. Miliano, N. Simola, P. Fadda, L. Fattore, M. Scherma, M.G. Ennas, R. Mostallino, G. Flore, M. De Felice, C. Sagheddu, M. Pistis, G. Di Chiara, and M.A. De Luca, *Repeated Exposure to Jwh-018 Induces Adaptive Changes in the Mesolimbic and Mesocortical Dopamine Pathways, Glial Cells Alteration and Behavioural Correlates.* (2021) **Br J Pharmacol**.

23. Sagheddu, C., M. Melis, A.L. Muntoni, and M. Pistis, *Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders.* (2021) **Pharmaceuticals (Basel)**. 14(10).

24. Devoto, P., C. Sagheddu, M. Santoni, G. Flore, P. Saba, M. Pistis, and G.L. Gessa, *Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex.* (2020) **Frontiers in Pharmacology**. 11(1530).

25. Murru, E., G. Carta, C. Manca, V. Sogos, M. Pistis, M. Melis, and S. Banni, *Conjugated Linoleic Acid and Brain Metabolism: A Possible Anti-Neuroinflammatory Role Mediated by PPARalpha Activation.* (2020) **Front Pharmacol**. 11: p. 587140.

26. Sagheddu, C., N. Pintori, P. Kalaba, V. Dragacevic, G. Piras, J. Lubec, N. Simola, M.A. De Luca, G. Lubec, and M. Pistis, *Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer (S)-CE-123 on Mesocorticolimbic Dopamine System.* (2020) **Biomolecules**. 10(5).

27. Sagheddu, C., L.H. Torres, T. Marcourakis, and M. Pistis, *Endocannabinoid-Like Lipid Neuromodulators in the Regulation of Dopamine Signaling: Relevance for Drug Addiction.* (2020) **Front Synaptic Neurosci**. 12: p. 588660.

28. Torres, L.H., C.C. Real, W.M. Turato, L.W. Spelta, A.C.C. Dos Santos Durao, T.C. Andrioli, L. Pozzo, P.L. Squair, M. Pistis, D. de Paula Faria, and T. Marcourakis, *Environmental Tobacco Smoke During the Early Postnatal Period of Mice Interferes With Brain (18) F-FDG Uptake From Infancy to Early Adulthood - A Longitudinal Study.* (2020) **Front Neurosci**. 14: p. 5.

29. Trifirò, G., S. Crisafulli, G. Andò, G. Racagni, and F. Drago, *Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?,* (2020) **Drug Saf**. 43(6): p. 507-509.

30. Congiu, M., M. Trusel, M. Pistis, M. Mameli, and S. Lecca, *Opposite responses to aversive stimuli in lateral habenula neurons.* (2019) **Eur J Neurosci**.

31. De Felice, M., M. Melis, S. Aroni, A.L. Muntoni, S. Fanni, R. Frau, P. Devoto, and M. Pistis, *The PPARalpha agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.* (2019) **CNS Neurosci Ther**. 25(5): p. 549-561.

32. Lecca, S., A. Luchicchi, M. Scherma, P. Fadda, A.L. Muntoni, and M. Pistis, *Δ9-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation.* (2019) **Frontiers in Behavioral Neuroscience**. 13(202).

33. Rotolo, R.A., V. Dragacevic, P. Kalaba, E. Urban, M. Zehl, A. Roller, J. Wackerlig, T. Langer, M. Pistis, M.A. De Luca, F. Caria, R. Schwartz, R.E. Presby, J.H. Yang, S. Samels, M. Correa, G. Lubec, and J.D. Salamone, *The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding.* (2019) **Front Pharmacol**. 10: p. 682.

34. Sagheddu, C., M. Scherma, M. Congiu, P. Fadda, G. Carta, S. Banni, J.T. Wood, A. Makriyannis, M.S. Malamas, and M. Pistis, *Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward.* (2019) **Neuropharmacology**. 144: p. 327-336.

35. Secci, M.E., P. Mascia, C. Sagheddu, S. Beggiato, M. Melis, A.C. Borelli, M.C. Tomasini, L.V. Panlilio, C.W. Schindler, G. Tanda, S. Ferre, C.W. Bradberry, L. Ferraro, M. Pistis, S.R. Goldberg, R. Schwarcz, and Z. Justinova, *Astrocytic Mechanisms Involving Kynurenic Acid Control Delta(9)-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.* (2019) **Mol Neurobiol**. 56(5): p. 3563-3575.

36. Torres, L.H., N.T. Balestrin, L.E.W. Spelta, S.O. Duro, M. Pistis, and T. Marcourakis, *Exposure to tobacco smoke during the early postnatal period modifies receptors and enzymes of the endocannabinoid system in the brainstem and striatum in mice.* (2019) **Toxicol Lett**. 302: p. 35-41.

37. Pistis, M. and S.E. O'Sullivan, *The Role of Nuclear Hormone Receptors in Cannabinoid Function.* (2017) **Adv Pharmacol**. 80: p. 291-328.

38. Puligheddu, M., M. Melis, G. Pillolla, G. Milioli, L. Parrino, G.M. Terzano, S. Aroni, C. Sagheddu, F. Marrosu, M. Pistis, and A.L. Muntoni, *Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.* (2017) **Epilepsia**. 58(10): p. 1762-1770.

39. Luchicchi, A., S. Lecca, M. Melis, M. De Felice, F. Cadeddu, R. Frau, A.L. Muntoni, P. Fadda, P. Devoto, and M. Pistis, *Maternal Immune Activation Disrupts Dopamine System in the Offspring.* (2016) **Int J Neuropsychopharmacol**. 19(7).

40. Scheggi, S., M. Melis, M. De Felice, S. Aroni, A.L. Muntoni, T. Pelliccia, C. Gambarana, M.G. De Montis, and M. Pistis, *PPARalpha modulation of mesolimbic dopamine transmission rescues depression-related behaviors.* (2016) **Neuropharmacology**. 110(Pt A): p. 251-9.

41. Scherma, M., C. Dessi, A.L. Muntoni, S. Lecca, V. Satta, A. Luchicchi, M. Pistis, L.V. Panlilio, L. Fattore, S.R. Goldberg, W. Fratta, and P. Fadda, *Adolescent Delta(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.* (2016) **Neuropsychopharmacology**. 41(5): p. 1416-26.

42. Scherma, M., A.L. Muntoni, M. Melis, L. Fattore, P. Fadda, W. Fratta, and M. Pistis, *Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.* (2016) **Psychopharmacology**. 233(10): p. 1765-77.

43. Dudok, B., L. Barna, M. Ledri, S.I. Szabo, E. Szabadits, B. Pinter, S.G. Woodhams, C.M. Henstridge, G.Y. Balla, R. Nyilas, C. Varga, S.H. Lee, M. Matolcsi, J. Cervenak, I. Kacskovics, M. Watanabe, C. Sagheddu, M. Melis, M. Pistis, I. Soltesz, and I. Katona, *Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling.* (2015) **Nature Neuroscience**. 18(1): p. 75-86.

44. Sagheddu, C., S. Aroni, M. De Felice, S. Lecca, A. Luchicchi, M. Melis, A.L. Muntoni, R. Romano, E. Palazzo, F. Guida, S. Maione, and M. Pistis, *Enhanced serotonin and mesolimbic dopamine transmissions in a rat model of neuropathic pain.* (2015) **Neuropharmacology**. 97: p. 383-93.

45. Sagheddu, C., A.L. Muntoni, M. Pistis, and M. Melis, *Endocannabinoid Signaling in Motivation, Reward, and Addiction: Influences on Mesocorticolimbic Dopamine Function.* (2015) **International Review of Neurobiology**. 125: p. 257-302.

46. Melis, M. and M. Pistis, *Targeting the interaction between fatty acid ethanolamides and nicotinic receptors: therapeutic perspectives.* (2014) **Pharmacological Research**. 86: p. 42-9.

47. Melis, M., C. Sagheddu, M. De Felice, A. Casti, C. Madeddu, S. Spiga, A.L. Muntoni, K. Mackie, G. Marsicano, G. Colombo, M.P. Castelli, and M. Pistis, *Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in Sardinian alcohol-preferring rats.* (2014) **Journal of Neuroscience**. 34(38): p. 12716-24.

48. Costa, M., A. Squassina, D. Congiu, C. Chillotti, P. Niola, S. Galderisi, M. Pistis, and M. Del Zompo, *Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-alpha gene (PPARA) and schizophrenia.* (2013) **European Neuropsychopharmacology**. 23(7): p. 749-59.

49. Justinova, Z., P. Mascia, H.Q. Wu, M.E. Secci, G.H. Redhi, L.V. Panlilio, M. Scherma, C. Barnes, A. Parashos, T. Zara, W. Fratta, M. Solinas, M. Pistis, J. Bergman, B.D. Kangas, S. Ferre, G. Tanda, R. Schwarcz, and S.R. Goldberg, *Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid.* (2013) **Nature Neuroscience**. 16(11): p. 1652-61.

50. Melis, M., G. Carta, M. Pistis, and S. Banni, *Physiological role of peroxisome proliferator-activated receptors type alpha on dopamine systems.* (2013) **CNS Neurol Disord Drug Targets**. 12(1): p. 70-7.

51. Melis, M., M. De Felice, S. Lecca, L. Fattore, and M. Pistis, *Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats.* (2013) **Front Integr Neurosci**. 7: p. 93.

52. Melis, M., S. Scheggi, G. Carta, C. Madeddu, S. Lecca, A. Luchicchi, F. Cadeddu, R. Frau, L. Fattore, P. Fadda, M.G. Ennas, M.P. Castelli, W. Fratta, B. Schilstrom, S. Banni, M.G. De Montis, and M. Pistis, *PPARalpha regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving alpha7 nicotinic acetylcholine receptors.* (2013) **Journal of Neuroscience**. 33(14): p. 6203-11.

53. Puligheddu, M., G. Pillolla, M. Melis, S. Lecca, F. Marrosu, M.G. De Montis, S. Scheggi, G. Carta, E. Murru, S. Aroni, A.L. Muntoni, and M. Pistis, *PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings.* (2013) **PloS one**. 8(5): p. e64541.

54. Barrot, M., S.R. Sesack, F. Georges, M. Pistis, S. Hong, and T.C. Jhou, *Braking Dopamine Systems: A New GABA Master Structure for Mesolimbic and Nigrostriatal Functions.* (2012) **J Neurosci**. 32(41): p. 14094-14101.

55. Lecca, S., M. Melis, A. Luchicchi, A.L. Muntoni, and M. Pistis, *Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse.* (2012) **Neuropsychopharmacology**. 37(5): p. 1164-76.

56. Luchicchi, A. and M. Pistis, *Anandamide and 2-arachidonoylglycerol: Pharmacological Properties, Functional Features, and Emerging Specificities of the Two Major Endocannabinoids.* (2012) **Molecular Neurobiology**. 46(2): p. 374-92.

57. Melis, M., A.L. Muntoni, and M. Pistis, *Endocannabinoids and the processing of value-related signals.* (2012) **Front Pharmacol**. 3: p. 7.

58. Melis, M. and M. Pistis, *Hub and switches: endocannabinoid signalling in midbrain dopamine neurons.* (2012) **Philos Trans R Soc Lond B Biol Sci**. 367(1607): p. 3276-85.

59. Panlilio, L.V., Z. Justinova, P. Mascia, M. Pistis, A. Luchicchi, S. Lecca, C. Barnes, G.H. Redhi, J. Adair, S.J. Heishman, S. Yasar, M. Aliczki, J. Haller, and S.R. Goldberg, *Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.* (2012) **Neuropsychopharmacology**. 37(8): p. 1838-47.

60. Lecca, S., M. Melis, A. Luchicchi, M.G. Ennas, M.P. Castelli, A.L. Muntoni, and M. Pistis, *Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells.* (2011) **Neuropsychopharmacology**. 36(3): p. 589-602.

61. Mascia, P., M. Pistis, Z. Justinova, L.V. Panlilio, A. Luchicchi, S. Lecca, M. Scherma, W. Fratta, P. Fadda, C. Barnes, G.H. Redhi, S. Yasar, B. Le Foll, G. Tanda, D. Piomelli, and S.R. Goldberg, *Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors.* (2011) **Biological Psychiatry**. 69(7): p. 633-41.

62. Fattore, L., M. Melis, P. Fadda, M. Pistis, and W. Fratta, *The endocannabinoid system and nondrug rewarding behaviours.* (2010) **Exp Neurol**. 224(1): p. 23-36.

63. Luchicchi, A., S. Lecca, S. Carta, G. Pillolla, A.L. Muntoni, S. Yasar, S.R. Goldberg, and M. Pistis, *Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors.* (2010) **Addict Biol**. 15(3): p. 277-288.

64. Melis, M., S. Carta, L. Fattore, S. Tolu, S. Yasar, S.R. Goldberg, W. Fratta, U. Maskos, and M. Pistis, *Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors.* (2010) **Biol Psychiatry**. 68(3): p. 256-64.

65. Pistis, M. and M. Melis, *From surface to nuclear receptors: the endocannabinoid family extends its assets.* (2010) **Current Medicinal Chemistry**. 17(14): p. 1450-1467.

66. Melis, M., G. Pillolla, S. Perra, G. Colombo, A.L. Muntoni, and M. Pistis, *Electrophysiological properties of dopamine neurons in the ventral tegmental area of Sardinian alcohol-preferring rats.* (2009) **Psychopharmacology (Berl)**. 201(4): p. 471-81.

67. Fattore, L., P. Fadda, M.S. Spano, M. Pistis, and W. Fratta, *Neurobiological mechanisms of cannabinoid addiction.* (2008) **Molecular and Cellular Endocrinology**. 286(1-2, Supplement 1): p. S97-S107.

68. Melis, M., G. Pillolla, A. Luchicchi, A.L. Muntoni, S. Yasar, S.R. Goldberg, and M. Pistis, *Endogenous Fatty Acid Ethanolamides Suppress Nicotine-Induced Activation of Mesolimbic Dopamine Neurons through Nuclear Receptors.* (2008) **J Neurosci**. 28(51): p. 13985-13994.

69. Perra, S., G. Pillolla, A. Luchicchi, and M. Pistis, *Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.* (2008) **Alcohol Clin Exp Res**. 32(3): p. 443-9.

70. Castelli, M.P., A. Paola Piras, A. D'Agostino, F. Pibiri, S. Perra, G.L. Gessa, M. Maccarrone, and M. Pistis, *Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.* (2007) **Eur J Pharmacol**. 573(1-3): p. 11-9.

71. Melis, M. and M. Pistis, *Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?,* (2007) **Current Neuropharmacology**. 5(4): p. 268-277.

72. Pillolla, G., M. Melis, S. Perra, A.L. Muntoni, G.L. Gessa, and M. Pistis, *Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo.,* (2007) **Psychopharmacology**. 191(3): p. 843-853.

73. Melis, M., G. Pillolla, T. Bisogno, A. Minassi, S. Petrosino, S. Perra, A.L. Muntoni, B. Lutz, G.L. Gessa, G. Marsicano, V. Di Marzo, and M. Pistis, *Protective activation of the endocannabinoid system during ischemia in dopamine neurons.* (2006) **Neurobiol Dis**. 24(1): p. 15-27.

74. Muntoni, A.L., G. Pillolla, M. Melis, S. Perra, G.L. Gessa, and **M. Pistis**, *Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons.* (2006) **Eur J Neurosci**. 23(9): p. 2385-94.

75. Perra, S., G. Pillolla, M. Melis, A.L. Muntoni, G.L. Gessa, and M. Pistis, *Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.* (2005) **Psychopharmacology (Berl)**. 183(3): p. 368-77.

76. Pistis, M., A.L. Muntoni, G. Pillolla, S. Perra, G. Cignarella, M. Melis, and G.L. Gessa, *Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects.* (2005) **Neuroscience**. 131(2): p. 465-74.

77. Melis, M., S. Perra, A.L. Muntoni, G. Pillolla, B. Lutz, G. Marsicano, V. Di Marzo, G.L. Gessa, and M. Pistis, *Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons.* (2004) **J Neurosci**. 24(47): p. 10707-15.

78. Melis, M., M. Pistis, S. Perra, A.L. Muntoni, G. Pillolla, and G.L. Gessa, *Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors.* (2004) **J Neurosci**. 24(1): p. 53-62.

79. Pistis, M., S. Perra, G. Pillolla, M. Melis, G.L. Gessa, and A.L. Muntoni, *Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions.* (2004) **Neuropharmacology**. 46(1): p. 115-25.

80. Pistis, M., S. Perra, G. Pillolla, M. Melis, A.L. Muntoni, and G.L. Gessa, *Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons.* (2004) **Biol Psychiatry**. 56(2): p. 86-94.

81. Sanna, A., E. Congeddu, A. Porcella, L. Saba, **M. Pistis**, M. Peis, G. Marchese, S. Ruiu, C. Lobina, D.R. Grayson, G.L. Gessa, and L. Pani, *Characterization of wild-type (R100R) and mutated (Q100Q) GABAA alpha 6 subunit in Sardinian alcohol non-preferring rats (sNP).* (2003) **Brain Res**. 967(1-2): p. 98-105.

82. Castelli, M.P., I. Mocci, **M. Pistis**, M. Peis, D. Berta, A. Gelain, G.L. Gessa, and G. Cignarella, *Stereoselectivity of NCS-382 binding to gamma-hydroxybutyrate receptor in the rat brain.* (2002) **Eur J Pharmacol**. 446(1-3): p. 1-5.

83. Pistis, M., L. Ferraro, L. Pira, G. Flore, S. Tanganelli, G.L. Gessa, and P. Devoto, *Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study.* (2002) **Brain Res**. 948(1-2): p. 155-8.

84. Pistis, M., A.L. Muntoni, G. Pillolla, and G.L. Gessa, *Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study.* (2002) **Eur J Neurosci**. 15(11): p. 1795-802.

85. Pistis, M., G. Porcu, M. Melis, M. Diana, and G.L. Gessa, *Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation.* (2001) **Eur J Neurosci**. 14(1): p. 96-102.

86. Saba, L., A. Porcella, E. Congeddu, G. Colombo, M. Peis, **M. Pistis**, G.L. Gessa, and L. Pani, *The R100Q mutation of the GABA(A) alpha(6) receptor subunit may contribute to voluntary aversion to ethanol in the sNP rat line.* (2001) **Brain Res Mol Brain Res**. 87(2): p. 263-70.

87. Gessa, G.L., P. Devoto, M. Diana, G. Flore, M. Melis, and M. Pistis, *Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.* (2000) **Neuropsychopharmacology**. 22(6): p. 642-9.

88. Belelli, D., **M. Pistis**, J.A. Peters, and J.J. Lambert, *General anaesthetic action at transmitter-gated inhibitory amino acid receptors.* (1999) **Trends Pharmacol Sci**. 20(12): p. 496-502.

89. Belelli, D., **M. Pistis**, J.A. Peters, and J.J. Lambert, *The interaction of general anaesthetics and neurosteroids with GABA(A) and glycine receptors.* (1999) **Neurochem Int**. 34(5): p. 447-52.

90. Davies, P.A., **M. Pistis**, M.C. Hanna, J.A. Peters, J.J. Lambert, T.G. Hales, and E.F. Kirkness, *The 5-HT3B subunit is a major determinant of serotonin-receptor function.* (1999) **Nature**. 397(6717): p. 359-63.

91. Diana, M., A.L. Muntoni, **M. Pistis**, M. Melis, and G.L. Gessa, *Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal.* (1999) **Eur J Neurosci**. 11(3): p. 1037-41.

92. **Pistis, M.**, D. Belelli, K. McGurk, J.A. Peters, and J.J. Lambert, *Complementary regulation of anaesthetic activation of human (alpha6beta3gamma2L) and Drosophila (RDL) GABA receptors by a single amino acid residue.* (1999) **J Physiol**. 515 (Pt 1): p. 3-18.

93. McGurk, K.A., **M. Pistis**, D. Belelli, A.G. Hope, and J.J. Lambert, *The effect of a transmembrane amino acid on etomidate sensitivity of an invertebrate GABA receptor.* (1998) **Br J Pharmacol**. 124(1): p. 13-20.

94. **Pistis, M.**, D. Belelli, J.A. Peters, and J.J. Lambert, *The interaction of general anaesthetics with recombinant GABAA and glycine receptors expressed in Xenopus laevis oocytes: a comparative study.* (1997) **Br J Pharmacol**. 122(8): p. 1707-19.

95. Pistis, M., A.L. Muntoni, G. Gessa, and M. Diana, *Effects of acute, chronic ethanol and withdrawal on dorsal raphe neurons: electrophysiological studies.* (1997) **Neuroscience**. 79(1): p. 171-6.

96. Diana, M., A.L. Muntoni, **M. Pistis**, M. Collu, A. Forgione, and G.L. Gessa, *Chronic administration of l-sulpiride at low doses reduces A10 but not A9 somatodentritic dopamine autoreceptor sensitivity.* (1996) **Eur J Pharmacol**. 312(2): p. 179-81.

97. Diana, M., **M. Pistis**, A. Muntoni, and G. Gessa, *Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence.* (1996) **Neuroscience**. 71(2): p. 411-5.

98. Devoto, P., M. Collu, A.L. Muntoni, M. Pistis, G. Serra, G.L. Gessa, and M. Diana, *Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system.* (1995) **Synapse**. 20(2): p. 153-5.

99. Diana, M., M. Pistis, A. Muntoni, and G. Gessa, *Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.* (1995) **J Pharmacol Exp Ther**. 272(2): p. 781-5.

100. Diana, M., **M. Pistis**, A.L. Muntoni, and G.L. Gessa, *Ethanol withdrawal does not induce a reduction in the number of spontaneously active dopaminergic neurons in the mesolimbic system.* (1995) **Brain Res**. 682(1-2): p. 29-34.

101. Diana, M., M. Pistis, S. Carboni, G.L. Gessa, and Z.L. Rossetti, *Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence.* (1993) **Proc Natl Acad Sci U S A**. 90(17): p. 7966-9.

102. Diana, M., **M. Pistis**, A. Muntoni, and G. Gessa, *Heterogeneous responses of substantia nigra pars reticulata neurons to gamma-hydroxybutyric acid administration.* (1993) **Eur J Pharmacol**. 230(3): p. 363-5.

103. Diana, M., **M. Pistis**, A. Muntoni, Z.L. Rossetti, and G. Gessa, *Marked decrease of A10 dopamine neuronal firing during ethanol withdrawal syndrome in rats.* (1992) **Eur J Pharmacol**. 221(2-3): p. 403-4.

CAPITOLI DI LIBRI

1) **Pistis M**, Muntoni AL. Roles of N-acylethanolamines in brain functions and neuropsychiatric diseases. Endocannabinoids and Lipid Mediators in Brain Functions 2017. p. 319-46.
2) M Melis, AL Muntoni, **Pistis M** (2013). Dynamic Interactions Between Drugs of Abuse and the Endocannabinoid System: Molecular Mechanisms and Functional Outcome. In: Eric Murillo-Rodríguez. (a cura di): Emmanuel S. Onaivi, Nissar A. Darmani & Edward Wagner, Endocannabinoids: Molecular, Pharmacological, Behavioral and Clinical Features. p. 132-163, Bentham Science Publishers, ISBN: 9781608051250, doi: 10.2174/978160805028411301001O

3) J.J. Lambert, D. Belelli, **M. Pistis**, C. Hill-Venning and J.A. Peters. (1996) The interaction of intravenous anesthetic agents with native and recombinant $GABA_A$ receptors. An electrophysiological study. In : The GABA receptors. Eds: S.J. Enna and N.G. Bowery. Humana Press Inc, Totowa. Nj. USA.

4) Lambert, J.J., Belelli, D., Shepherd, S.E., Muntoni, A.L., **Pistis, M.** and Peters, J.A. (1998) The GABAA receptor: an important locus for intravenous anaesthetic action. In: Gases in Medicine: Anaesthesia, 8th BOC Priestly Conference. Eds. Smith E.D. and Daniels S. pp121-152. Roy. Soc.Chemistry, Cambridge.

5) Lambert, J.J., Belelli, D.,Shepherd, S.E., **Pistis, M.** and Peters, J.A. (1999) The selective interaction of neurosteroids with the GABAA receptor. In: Neurosteroids: A New Regulatory Function in the Nervous System. Eds. E.E. Baulieu, P. Robel. and M. Schumacher, Eds. Humana Press, Totowa,NJ, USA

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

Cagliari, 28 marzo 2025

Marco Pistis